Galactomannan in Piperacillin-Tazobactam: How Much and to What Extent?
Open Access
- 1 September 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (9) , 3984-3985
- https://doi.org/10.1128/aac.49.9.3984-3985.2005
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Lack of Evidence That False-Positive Aspergillus Galactomannan Antigen Test Results Are Due to Treatment with Piperacillin-TazobactamClinical Infectious Diseases, 2004
- Detection of Galactomannan Antigenemia in Patients Receiving Piperacillin-Tazobactam and Correlations between In Vitro, In Vivo, and Clinical Properties of the Drug-Antigen InteractionJournal of Clinical Microbiology, 2004
- Reactivity of Platelia Aspergillus Galactomannan Antigen with Piperacillin-Tazobactam: Clinical Implications Based on Achievable Concentrations in SerumAntimicrobial Agents and Chemotherapy, 2004
- Treatment with Piperacillin‐Tazobactam and False‐PositiveAspergillusGalactomannan Antigen Test Results for Patients with Hematological MalignanciesClinical Infectious Diseases, 2004
- False‐Positive Galactomannan PlateliaAspergillusTest Results for Patients Receiving Piperacillin‐TazobactamClinical Infectious Diseases, 2004
- False Positive Test for Aspergillus Antigenemia Related to Concomitant Administration of Piperacillin and TazobactamNew England Journal of Medicine, 2003
- Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validationBlood, 2001
- Methodological issues in assessing reproducibility—A comparative study of various indices of reproducibility applied to repeat ELISA serologic tests for Lyme diseaseJournal of Clinical Epidemiology, 1995